Pier 88 Investment Partners LLC Purchases 170 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Pier 88 Investment Partners LLC lifted its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 5.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,530 shares of the company’s stock after acquiring an additional 170 shares during the quarter. Pier 88 Investment Partners LLC’s holdings in Krystal Biotech were worth $643,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Scout Investments Inc. bought a new stake in shares of Krystal Biotech during the 1st quarter worth $8,976,000. Sei Investments Co. raised its position in Krystal Biotech by 128.3% in the first quarter. Sei Investments Co. now owns 33,752 shares of the company’s stock worth $6,005,000 after acquiring an additional 18,968 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Krystal Biotech by 54.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock valued at $117,189,000 after acquiring an additional 231,255 shares during the last quarter. Shaker Investments LLC OH bought a new position in shares of Krystal Biotech during the 3rd quarter valued at approximately $532,000. Finally, Amalgamated Bank grew its position in shares of Krystal Biotech by 937.9% during the 2nd quarter. Amalgamated Bank now owns 7,577 shares of the company’s stock valued at $1,391,000 after acquiring an additional 6,847 shares during the period. 86.29% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

KRYS has been the topic of several research analyst reports. Citigroup upped their price objective on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Stifel Nicolaus upped their price target on Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Chardan Capital lifted their price objective on Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a report on Monday, August 5th. HC Wainwright reaffirmed a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a report on Tuesday, November 5th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Krystal Biotech presently has a consensus rating of “Buy” and an average target price of $197.00.

Krystal Biotech Trading Down 1.6 %

Shares of NASDAQ KRYS opened at $184.22 on Thursday. The business has a 50-day moving average of $181.31 and a 200-day moving average of $181.36. The firm has a market capitalization of $5.30 billion, a price-to-earnings ratio of 104.08 and a beta of 0.82. Krystal Biotech, Inc. has a 12 month low of $96.73 and a 12 month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. The business had revenue of $83.84 million during the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business’s quarterly revenue was up 879.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.67) EPS. On average, analysts predict that Krystal Biotech, Inc. will post 2.97 earnings per share for the current year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the sale, the insider now owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 14.10% of the stock is owned by insiders.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).